

Axial spondyloarthritis - Pipeline Insight, 2021

<https://marketpublishers.com/r/A03240B601BEN.html>

Date: May 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: A03240B601BEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Axial spondyloarthritis - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Axial spondyloarthritis Understanding

Axial spondyloarthritis: Overview

The term axial spondyloarthritis covers both the early inflammatory phase of the disease in which there is no structural damage in the sacroiliac joints (non-radiographic disease) and the later stages in which structural damage is visible on X-ray scans of the sacroiliac joints as erosions, sclerosis or bony bridges (radiographic disease; also known as ankylosing spondylitis). In addition, patients with radiographic axial spondyloarthritis might have abnormalities in X-ray scans of the spine, the most important one being syndesmophytes (vertical bony growth between the corners of two vertebral bodies).

Axial spondyloarthritis is divided into non-radiographic and radiographic disease (also

known as ankylosing spondylitis) according to the presence of radiographic changes of the sacroiliac joints. Changes in the spine evident on X-ray can occur in radiographic axial spondyloarthritis, but spinal radiographs can also be normal.

'Axial spondyloarthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided which includes the disease overview and Axial spondyloarthritis treatment guidelines. The assessment part of the report embraces, in depth Axial spondyloarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial spondyloarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Axial spondyloarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Axial spondyloarthritis.

Axial spondyloarthritis Emerging Drugs Chapters

This segment of the Axial spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axial spondyloarthritis Emerging Drugs

Tofacitinib: Pfizer

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that

affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs.

Bimekizumab: UCB Biopharma

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. The drug is currently in phase 3 of development stage for the treatment of Axial spondylarthritis.

Tildrakizumab: Sun Pharma Global

Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of the interleukin-23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 plays a critical role in modulating inflammatory and immune responses. In March 2018, the biological treatment tildrakizumab (Ilumya) received US Food and Drug Administration (FDA) approval for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.

Further product details are provided in the repor

Axial spondyloarthritis: Therapeutic Assessment

This segment of the report provides insights about the different Axial spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Axial spondyloarthritis

There are approx. 30+ key companies which are developing the therapies for Axial spondyloarthritis. The companies which have their Axial spondyloarthritis drug candidates in the most advanced stage, i.e. phase III include, UCB Biopharma.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Axial spondyloarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Oligonucleotide

Recombinant fusion proteins

Small molecule

Peptide vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axial spondyloarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial spondyloarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial spondyloarthritis drugs.

Axial spondyloarthritis Report Insights

Axial spondyloarthritis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Axial spondyloarthritis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Axial spondyloarthritis drugs?

How many Axial spondyloarthritis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial spondyloarthritis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial spondyloarthritis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Axial spondyloarthritis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfizer

Mycenax Biotech

Clover Biopharmaceuticals

Celltrion

UCB

Gilead Sciences

Amgen

Genrix (Shanghai) Biopharmaceuticals

Sun Pharma Global

Boehringer Ingelheim

Jiangsu HengRui Medicine

Izana Bioscience

3SBio

Tasly Pharmaceuticals Inc.

Suzhou Zelgen Biopharmaceuticals

Affibody

Kinevant Sciences

Qyuns Therapeutics

Akeso Biopharma

Jiangsu HengRui Medicine Co., Ltd

FunPep Co Ltd.

Luye Pharma Group

siRNAgen Therapeutics

Aclaris Therapeutics

Dice molecules

Key Products

Tofacitinib

ENIA11

SCB-808

CT-P17

Bimekizumab

Filgotinib

Apremilast

GR1501

Tildrakizumab

BI 730357

SHR0302

Namilumab

SSS07

Jitongning tablets

Jaktinib

ABY-035

KIN-1901

QX002N

AK111

SHR-1314

FPP003

TS8108

Amphisiran

Contents

Introduction

Executive Summary

Axial spondyloarthritis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Axial spondyloarthritis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Axial spondyloarthritis companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Axial spondyloarthritis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Bimekizumab: UCB Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Namilumab: Izana Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

KIN-1901: Kinevant Sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Axial spondyloarthritis Key Companies

Axial spondyloarthritis Key Products

Axial spondyloarthritis- Unmet Needs

Axial spondyloarthritis- Market Drivers and Barriers

Axial spondyloarthritis- Future Perspectives and Conclusion

Axial spondyloarthritis Analyst Views

Axial spondyloarthritis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Axial spondyloarthritis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Axial spondyloarthritis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Axial spondyloarthritis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A03240B601BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A03240B601BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970